The Epidermal Growth Factor Receptor (EGFR) is expressed on the cell surface and has tyrosine kinase activity. EGFR regulates the cell cycle via the MAPK/ERK and PI3K/AKT/mTOR pathways. Activating mutations of EGFR leads to induction of its kinase activity, which results to uncontrolled cell proliferation.
This is used in the cancer treatment by so-called tyrosine kinase inhibitors (TKIs), which bind to the ATP receptor binding site and inhibit EGFR activity. On the other side, the T790M mutation found in exon 20 leads to the TKI resistance.
Anti-EGFR TKIs are particularly useful in the treatment of lung tumors, especially non-small cell lung cancer. However, resistance to TKI develops very quickly (median 9–13 months). Therefore, detection of the T790M mutation is required before the treatment with TKI-group medicinal products.
Parametres of the diagnostic kit
- qPCR assay + Master Mix
- LOD 0.05% mutated EGFR on WT background at 100,000 copies in reaction
- sample concentration 10-80 ng/µl
- positive and negative controls are included
- FAM channel detection
- identical amplification profile as gb HEMO, gb GENETIC, gb PHARM kits